This brand name is authorized in Tunisia
The drug MOXONYL contains one active pharmaceutical ingredient (API):
|
1
Moxonidine
UNII CC6X0L40GW - MOXONIDINE
|
|
Moxonidine has been shown to bind selectively to the I1-imidazoline receptors in the brain stem. These imidazoline-sensitive receptors are concentrated in the rostral ventrolateral medulla, an area which is of crucial importance for central control of the peripheral sympathetic nervous system. The result of this effect on the I1-imidazoline receptors has been apparent in reduced activity in the sympathetic nerves. (demonstrated for cardiac, splanchnic and renal sympathetic nerves). |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C02AC05 | Moxonidine | C Cardiovascular system → C02 Antihypertensives → C02A Antiadrenergic agents, centrally acting → C02AC Imidazoline receptor agonists |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: TN | Direction de la Pharmacie et du Médicament | Identifier(s): 9373531, 9373532 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
